LEO Pharma
↗Ballerup, Copenhagen, Denmark
LEO Pharma is a multinational Danish pharmaceutical company founded in 1908, headquartered in Ballerup, Denmark, with a presence in approximately 100 countries. The company specializes in dermatology, thrombosis, coagulation, and bone remodeling therapeutics. LEO Pharma has a rich history of pharmaceutical innovation, including being the first company outside the UK and US to produce penicillin during World War II, and funding groundbreaking insulin research in Denmark. Today, the company operates with over 6,000 employees globally and is powered by more than 750 scientists and specialists focusing on dermatology and thrombosis research. In 2024-2025, LEO Pharma achieved strategic milestones including FDA approval of Anzupgo (delgocitinib), its first-in-class topical JAK inhibitor for chronic hand eczema, and expanded approvals for its flagship biologic Adbry (tralokinumab) for atopic dermatitis.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharmaceuticals - Dermatology and Thrombosis
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$1.5B-$2B (2024: DKK 12.45B / ~$1.67B)
Founded:1908
Ownership:private
Status:operating
FUNDING
Stage:Mature company
Investors:LEO Foundation (80% ownership via LEO Holding A/S), Nordic Capital (20% ownership, invested 2021)
PIPELINE
Stage:Phase 2, Phase 3, and Commercial
Lead Drug Stage:Commercial (Adbry/Adtralza, Anzupgo)
Modalities:Small molecule, mAb (monoclonal antibodies), Topical treatments, Injectable biologics
Active Trials:64
Trial Phases:Phase 2: 15 | Phase 3: 8 | Phase 4: 5
FDA Approvals:2
EMA Approvals:2
CORPORATE STRUCTURE
Subsidiaries:LEO Pharma Inc. (North America), LEO Labs (associated entity)
Key Partnerships:Gilead Sciences - January 2025 strategic partnership for oral STAT6 programs; LEO Pharma eligible for up to $1.7B in payments, Boehringer Ingelheim - July 2024 licensing agreement for Spevigo (spesolimab); $105M upfront deal for GPP treatment, ICON - Strategic CRO partnership for clinical trial execution in medical dermatology, Parker Institute, Copenhagen University Hospital - Three-year research collaboration for clinical trial design and AI analytics, Elektrofi - Collaboration on antibody development for improved drug delivery, DKSH - Partnership for Asia distribution of dermatology and thrombosis products, AstraZeneca - Historical licensing agreements in skin diseases
COMPETITION
Position:Challenger
Competitors:Novartis, Sanofi, AbbVie, Roche, Johnson & Johnson, AstraZeneca, Bayer, GSK +3 more
LEADERSHIP
Key Executives:
Christophe Bourdon - Chief Executive Officer (CEO)
Philip Eickhoff - Chief Financial Officer (CFO)
Sven Hauptmann - Executive Vice President, Technical Development and Supply
Brian Hilberdink - Executive Vice President, Region North America
Kreesten Meldgaard Madsen - Chief Development Officer (CDO), Global Development
Michael Meyer - Executive Vice President, Global People & Corporate Affairs
Becki Morison - Executive Vice President, Global Product Strategy & International Operations
Jacob Pontoppidan Thyssen - Chief Scientific Officer (CSO), Research & Early Development
Mark Levick - Interim EVP of Development (Board Member)
Scientific Founders:August Kongsted, Anton Antons
Board Members:Jesper Brandgaard (Chairman of the Board), Liisa Hurme (Independent Board Member (elected March 2025)), Mark Levick (Board Member, Chair of Innovation Committee (elected March 2025))
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with LEO Pharma. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.